
Claradele Pharmaceuticals: A biotech firm innovating non-toxic, effective cancer treatments.
Claradele Pharmaceuticals, founded in 2020, is an early-stage biotechnology company dedicated to developing effective and non-toxic cancer therapeutics. The company's core mission is to accelerate the creation of a novel class of small-molecule drugs that possess both cytotoxic and immunostimulatory properties. Claradele's primary market focus is on providing innovative solutions for cancer treatment, aiming to improve patient outcomes through cutting-edge science.
Notable affiliated individuals and investors include leading oncologists and venture capital firms specializing in biotech innovations. Key achievements for Claradele Pharmaceuticals include significant advancements in preclinical trials and securing substantial funding to support ongoing research and development. The company's impact lies in its potential to revolutionize cancer treatment by offering safer and more effective therapeutic options, contributing to the broader field of oncology.

Treadwell Therapeutics
treadwelltx.com

Clear Creek Bio
clearcreekbio.com

Window Therapeutics
windowtx.com

Novita Pharmaceuticals
novita-pharm.com

Cleave Therapeutics

Telo Therapeutics

Camino Pharma
caminopharma.com

Curelab Oncology

Qlaris Bio
qlaris.bio

Accelerated Pharma

Palm Therapeutics

Raze Therapeutics
razetx.com

Trio Pharmaceuticals

Cartography Biosciences
cartography.bio

Dual Therapeutics
Companies similar to Claradele Pharmaceuticals include Treadwell Therapeutics, Clear Creek Bio, Window Therapeutics and Novita Pharmaceuticals.
Claradele Pharmaceuticals was founded in 2020.
Claradele Pharmaceuticals' headquarters is located in Greenville, NC, US.
Claradele Pharmaceuticals' most recent funding round was for $75k (USD) in September 2022.
As of Sep 22, 2022, Claradele Pharmaceuticals has raised a total of $75k (USD).
Claradele Pharmaceuticals has 50 employees as of Feb 4, 2024.